William E. Rote Sells 5,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 5,200 shares of the company’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the transaction, the senior vice president now owns 98,519 shares in the company, valued at $2,318,152.07. This represents a 5.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Travere Therapeutics Trading Up 2.2 %

Shares of TVTX stock opened at $23.72 on Friday. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The business’s 50 day moving average is $19.14 and its two-hundred day moving average is $16.01. The company has a market cap of $1.85 billion, a PE ratio of -5.21 and a beta of 0.72.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TVTX. CWM LLC grew its holdings in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares during the last quarter. Creative Planning grew its holdings in Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after purchasing an additional 995 shares during the last quarter. Semanteon Capital Management LP acquired a new position in Travere Therapeutics during the third quarter valued at approximately $513,000. China Universal Asset Management Co. Ltd. grew its holdings in Travere Therapeutics by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company’s stock valued at $206,000 after purchasing an additional 5,767 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its holdings in Travere Therapeutics by 24.4% during the third quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company’s stock valued at $1,325,000 after purchasing an additional 18,562 shares during the last quarter.

Wall Street Analyst Weigh In

TVTX has been the topic of a number of research reports. Evercore ISI upped their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday. Piper Sandler upped their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. HC Wainwright upped their target price on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Cantor Fitzgerald initiated coverage on Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating on the stock. Finally, Barclays upped their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.